AI Helps Fight Bad Bacteria, but Money Still Holds Them Back

Artificial intelligence can now sift through millions of molecules in a few days, spotting potential new antibiotics that would have taken years to find. It can even spot clues in ancient DNA or design fresh compounds from scratch, giving scientists new tools to battle drug‑resistant bacteria. But the real problem is not the science – it’s the market. Antibiotics are used for short courses and are kept scarce to avoid resistance, so companies earn little money from selling them. Even a brand‑new drug will be sold at low prices, taken off the market when cheaper generics appear, and rarely used in everyday practice. Because of this, investors shy away from the expensive late‑stage trials that are needed to bring a new drug to market. The result is a shrinking pipeline of antibiotics. Only about eleven new drugs target the most dangerous bacteria, and most of them are only modest improvements on existing medicines. Researchers who use AI to discover promising molecules often find no partners willing to fund the costly work of building and testing them. Hundreds of potentially useful candidates end up untested, sitting in supplemental data files rather than on shelves.Young scientists are leaving the field for other areas with steadier funding and clearer career paths, creating a “brain drain” that hurts future progress. The most efficient parts of AI – finding early hits, predicting toxicity, and narrowing the list of candidates – help reduce risk in the first stages. They do not fix the deeper issue that antibiotics are a public good, not a profitable product. Policymakers can change the equation by paying for access rather than volume, or by offering rewards that guarantee returns for truly innovative antibiotics. Several countries have already tried such models, and they show promise in encouraging investment. If governments value antibiotics properly, private companies will see a chance to profit and will use AI’s full power to accelerate discovery. Until the market changes, new antibiotics will remain rare and untested, patients will suffer from resistant infections, and brilliant AI‑driven ideas may stay locked in academic papers. The fight against antibiotic resistance needs both scientific breakthroughs and a new business model that rewards the life‑saving work.